DEVICE Act of 2025

Bill Number

H.R. 2372

Origin Chamber

House

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-03-26: Referred to the House Committee on Energy and Commerce.

Last Updated

2025-04-07T13:05:58Z

AI-Generated Summary

Purpose of the Legislation

The DEVICE Act of 2025 aims to improve the safety and cleanliness of medical devices by requiring manufacturers to report certain changes and communications to the U.S. Food and Drug Administration (FDA). It focuses on enhancing transparency about device design modifications, reprocessing instructions (methods to clean and reuse devices), and safety issues, while promoting tools to verify proper cleaning.

Key Provisions

• Reporting Changes to Device Design or Reprocessing Instructions (Section 2): Manufacturers must provide written notice to the FDA before altering the design of a device sold across state lines or changing instructions for reprocessing it. Failure to report makes the device "adulterated" (unsafe or non-compliant under law).
• Reporting Communications to Foreign Health Care Providers (Section 3): Manufacturers (or their affiliates, defined as related business entities under common control) must notify the FDA within 5 days of widely sharing information with foreign health care providers about device design changes, reprocessing protocol updates, or safety concerns. This applies to voluntary or other broad disseminations abroad.
• Rapid Assessment Tests for Reprocessing (Section 4):
• Expands the legal definition of a "device" to include rapid assessment tests (quick checks to confirm proper cleaning) for reusable devices (those intended for multiple uses after sanitization via cleaning, disinfection, or sterilization).
• Requires the FDA to create and update a list of these tests. For listed tests, manufacturers must submit validated instructions for use (proven effective methods) and supporting validation data (evidence of reliability) when seeking FDA clearance.
• Enforcement begins after the FDA publishes its initial list, about one year after the law's enactment.

Significant Changes to Existing Law

• Amends Section 501 of the Federal Food, Drug, and Cosmetic Act to classify non-reporting of design/reprocessing changes or foreign communications as adulteration, strengthening penalties for non-compliance.
• Adds new subsections (r), (s), and (t) to Section 510, introducing mandatory pre-change notifications, post-communication reporting, and data requirements for reprocessing tests—expanding beyond current premarket notification rules (often called 510(k) clearances).
• Broadens Section 201's device definition to explicitly cover reprocessing verification tools, which were not previously highlighted, and defines "reusable device" for clarity.

Potential Impacts

• On Government Agencies: The FDA will gain more oversight responsibilities, including reviewing reports, developing lists of tests, and enforcing new rules, potentially increasing workload and resource needs for device regulation.
• On Citizens and Health Care: Patients and providers may benefit from safer, cleaner reusable devices through better-verified reprocessing and timely awareness of changes or risks, reducing infection or malfunction hazards in medical settings.
• On Manufacturers: Increased reporting and validation requirements could raise compliance costs and administrative burdens, especially for companies operating internationally.
• On International Relations: By mandating U.S. reporting of foreign communications, the law may indirectly influence global device safety standards, encouraging alignment with FDA expectations abroad without directly affecting foreign regulations.

Main Stakeholders Affected

• Medical Device Manufacturers: Primary targets, facing new reporting and data submission obligations.
• FDA: Responsible for enforcement, list development, and review processes.
• Health Care Providers: Domestic and foreign providers gain access to more transparent safety information but may need to adapt to updated protocols.
• Patients and End-Users: Indirect beneficiaries through enhanced device safety and cleanliness.

Notable Legal, Constitutional, or Political Implications

• Legal: Strengthens FDA's regulatory authority over medical devices by tying non-reporting to adulteration status, potentially leading to more recalls or seizures for violations; no changes to due process or FDA clearance timelines are introduced.
• Constitutional: Aligns with Congress's commerce clause powers to regulate interstate products; no apparent free speech issues, as reporting targets safety-related business communications rather than restricting expression.
• Political: Promotes public health priorities by addressing device reprocessing risks (e.g., from past contamination incidents), but could spark industry debates over regulatory burdens in a politically divided Congress focused on innovation versus safety.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Lieu, Ted [D-CA-36]

Cosponsors (2)

Rep. Chu, Judy [D-CA-28], Del. Norton, Eleanor Holmes [D-DC-At Large]

Recent Actions

• 2025-03-26: Referred to the House Committee on Energy and Commerce.
• 2025-03-26: Introduced in House
• 2025-03-26: Introduced in House

Bill Versions

• Disclosure; and Encouragement of Verification, Innovation, Cleaning, and Efficiency Act of 2025 — issued 2025-03-26 — PDF (6 pages)